Research Guide
Tesamorelin: A Research Guide
Tesamorelin is the only compound in our catalog with completed Phase 3 clinical trial data. It is studied for its high degree of selectivity toward visceral adipose tissue, the metabolically active fat surrounding internal organs, while preserving lean muscle mass.
Sources
Falutz et al., NEJM 2007; Stanley et al., J Clin Endocrinol Metab 2012; Baker et al., 2012. For research use only. Not approved by the FDA. Not medical advice.
Mechanism
Phase 3 EGRIFTA trial data shows an 18% reduction in visceral fat by MRI, compared to just 3% in subcutaneous fat, demonstrating strong depot selectivity uncommon among fat-loss-associated compounds. A secondary analysis also found a 26% improvement in executive function scores among subjects with mild cognitive impairment, attributed in the literature to IGF-1's neuroprotective effects and reduced inflammatory burden from visceral fat.
Reconstitution & Storage
This compound is supplied as a lyophilized powder. Reconstitute with bacteriostatic water before use, using the calculator on our FAQ page to determine concentration and draw volume.
Open the reconstitution & dosing calculator →
Referenced Research Protocols
EGRIFTA Phase 3 protocols used daily dosing schedules over extended trial periods. This guide reflects published trial design, not usage instructions.